The compound library
With more than 10 years of accumulation, KBP has built a small molecule compound library with over 3,000,000 chemical compounds consisting of compounds designed and synthesized by KBP with unique chemical structures and high potency, compounds synthesized based on different core structures that cover almost all known core structures, and a natural product library of compounds extracted from plants, marine organisms and microorganisms.
Coupled with our bio-evaluation technology platform, the compound library enables KBP to identify and progress unique drugs that fit global unmet medical need quickly and efficiently.
Over 100 lead compounds have been screened from the library, and 3 compounds have entered into international clinical development.
The Bacteria Collection
KBP’s bacteria collection has more than 30,000 isolates, including Gram-positive and Gram-negative aerobic bacteria, anaerobic bacteria and clinical special pathogenic strains, covering 33 species and more than 200 classes of strains. KBP has established cooperative relations with more than 20 top hospitals (mostly in China), and will continue to find new partners for collecting difficult isolation strains, such as Anaerobic bacteria and Helicobacter pylori.
We are continually increasing the type and number of strains in our bacteria collection which will enable the development of new antibiotics that address the constantly growing global unmet medical needs as they exist today and as they evolve in the future.
Pharmacological experiment platform
KBP’s own pharmacology experimental platform is the basis for compound screening, optimization, preclinical pharmacology, toxicology, and pharmacological mechanisms study. The pharmacological experiment platform was established around three major areas (organ protection, inflammation and autoimmune, anti-infection). The platform includes pharmacology models, toxicology model and pharmacokinetic model, across different animal models.
The platform is well integrated with KBP’s compound library and the bacteria collection. The pharmacology experimental platform allows KBP to identify and progress those products with significant differentiation.